TOMASZ BEER, MD: And then docetaxel came along, which not only improved upon mitoxantrone with regard to pain control, but also provided for the first time a benefit with regard to survival in men who have advanced metastatic prostate cancer and who are no longer responding to hormonal therapy.
ANNOUNCER: Docetaxel, under the brand name Taxotere, has been proven to not only alleviate symptoms of cancer, but it also has shown a survival benefit.
CELESTIA S. HIGANO, MD: In the clinical trials, the median time -- that means half the patients -- lived as long as 18 to 19 months, and half the patients lived less long. And that is a two-month improvement over the median for the other combination, which was mitoxantrone and prednisone.
But I think that when you say there’s a two-month survival advantage, some people are rather shocked at how short that is. But this is for a whole group of men. This is not what the individual may get. And in fact, we’ve had some excellent, good long-term results with patients. I have patients who have had metastatic prostate cancer on and off chemotherapy for over five years.
ANNOUNCER: Currently docetaxel plus prednisone is the FDA-approved regimen for advanced prostate cancer. But researchers are also testing docetaxel with other agents in a number of clinical trials.
CELESTIA S. HIGANO, MD: We’re at the beginning of a big learning experience about what other drugs we can combine with docetaxel to improve on what we’ve seen with docetaxel and prednisone.